Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 6/20 | 1.00 |
| ▸ | PRKCG | P05129 | 5/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 5/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 5/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 4/20 | 1.00 |
| ▸ | PRKACG | P22612 | 4/20 | 1.00 |
| ▸ | PRKACB | P22694 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKCB | P05771 | 4/20 | 1.00 |
| ▸ | PRKCA | P17252 | 4/20 | 1.00 |
| ▸ | PRKCH | P24723 | 4/20 | 1.00 |
| ▸ | PRKCI | P41743 | 4/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 4/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 4/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | AKT2 | P31751 | 3/20 | 1.00 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967929 | 1.00 | PRKACA (1.00) | PRKACAPRKCGPRKCZPRKCDROCK2 | |
| SCHEMBL123496 | 1.00 | PRKACA (1.00) | PRKACAPRKCGPRKCZPRKCDROCK2 | |
| Hydrochloric Acid SCHEMBL29967768 | 0.99 | PRKACA (1.00) | PRKACAPRKCGPRKCZPRKCDROCK2 | |
| Bromide SCHEMBL3347119 | 0.99 | PRKACA (0.98) | PRKACAPRKCGPRKCZPRKCDROCK2 | |
| Bromide SCHEMBL3347113 | 0.99 | PRKACA (0.98) | PRKACAPRKCGPRKCZPRKCDROCK2 | |
| Hydrochloric Acid SCHEMBL29664044 | 0.99 | PRKACA (1.00) | PRKACAPRKCGPRKCZPRKCDROCK2 | |
| Hydrochloric Acid SCHEMBL1048972 | 0.99 | PRKACA (1.00) | PRKACAPRKCGPRKCZPRKCDROCK2 | |
| Hydrochloric Acid SCHEMBL905696 | 0.99 | PRKACA (1.00) | PRKACAPRKCGPRKCZPRKCDROCK2 | |
| Hydrochloric Acid SCHEMBL1048974 | 0.99 | PRKACA (1.00) | PRKACAPRKCGPRKCZPRKCDROCK2 | |
| SCHEMBL9636264 | 0.91 | PRKACA (0.83) | PRKACAPRKCGPRKCZPRKCDROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 491 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4512480-A2 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| EP-3082423-B1 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2024-12-11 | — | — | EP | claimed |
| EP-4389225-A2 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2024-06-26 | — | — | EP | claimed |
| US-20230355678-A1 | METHODS FOR IMPROVING T CELL EFFICACY | Immatics US, Inc. | 2023-11-09 | — | — | US | claimed |
| WO-2023215825-A1 | METHODS FOR IMPROVING T CELL EFFICACY | Immatics US, Inc. (US) | 2023-11-09 | — | — | WO | claimed |
| US-11723923-B2 | Methods of preparing T cells for T cell therapy | KITE PHARMA, INC. (US) | 2023-08-15 | — | — | US | claimed |
| EP-3082779-B1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-116036278-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| JP-2001510796-A | — | — | 2001-08-07 | — | — | JP | claimed |
| WO-2001040438-A2 | METHODS AND COMPOSITIONS FOR REGULATING LYMPHOCYTE ACTIVITY | CURIS, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| EP-1067917-A2 | METHOD OF TREATING DOPAMINERGIC AND GABA-NERGIC DISORDERS | Curis, Inc. (US) | 2001-01-17 | — | — | EP | claimed |
| EP-1028741-A1 | REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO | Ontogeny, Inc. (US) | 2000-08-23 | — | — | EP | claimed |
| EP-1009424-A2 | REGULATION OF MUSCLE TISSUES BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO | Ontogeny, Inc. (US) | 2000-06-21 | — | — | EP | claimed |
| WO-2000027422-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PERIPHERAL NEUROPATHIES | BIOGEN, INC. (US) | 2000-05-18 | — | — | WO | claimed |
| WO-1999004775-A9 | METHOD OF TREATING DOPAMINERGIC AND GABA-NERGIC DISORDERS | ONTOGENY INC (US) | 1999-04-29 | — | — | WO | claimed |
| WO-1999020298-A1 | REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO | ONTOGENY, INC. (US) | 1999-04-29 | — | — | WO | claimed |
| WO-1999010004-A2 | REGULATION OF MUSCLE TISSUES BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO | ONTOGENY, INC. (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1999004775-A2 | METHOD OF TREATING DOPAMINERGIC AND GABA-NERGIC DISORDERS | ONTOGENY, INC. (US) | 1999-02-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355678-A1 | METHODS FOR IMPROVING T CELL EFFICACY | ICOS, IL2, CD4 | PRKACA 338/4885PRKCG 576/4885PRKCZ 836/4885 |
| US-11723923-B2 | Methods of preparing T cells for T cell therapy | IL15, CD4, IL2 | PRKACA 233/4885PRKCG 615/4885PRKCZ 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.